A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia

Vogler, William R.; Winton, Elliott F.

doi:10.1016/0002-9343(77)90200-5

Cited by 166 publications

(83 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,12 This new technology was rapidly applied to the clinical setting, and through the 1970s several controlled studies investigated the role of GTX in the treatment of neutropenic sepsis (reviewed by Strauss, 1993). Although a benefit could be shown for GTX in some studies, [13][14][15] this was not a universal finding. 16,17 Concerns were also raised about the toxicity of GTX with infusion-related complications being reported, 18 and the recognition that the coadministration of amphotericin led to significant pulmonary adverse events.…”

Section: Historical Aspects Of Granulocyte Transfusionsmentioning

confidence: 90%

Granulocyte transfusions in the G-CSF era. Where do we stand?

Robinson

Marks

2004

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Historical Aspects Of Granulocyte Transfusionsmentioning

confidence: 90%

Granulocyte transfusions in the G-CSF era. Where do we stand?

Robinson

Marks

2004

Bone Marrow Transplant

View full text Add to dashboard Cite

“…We observed that 2-3 weekly transfusions prevented progression or de novo development of bacterial and fungal infections along with standard antimicrobial treatment. [21][22][23][24][25] Larger randomized studies are required to confirm the efficacy of prophylactic GTs in such patients and in particular to assess the potential of GTs for reducing aGvHD.…”

Section: Discussionmentioning

confidence: 99%

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Nikolajeva

Mijović

Hess

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Bacterial and fungal infections remain a significant cause of transplant-related mortality following allogeneic stem cell transplantation (SCT). Granulocyte transfusions (GTs) may reduce the neutropenic period after SCT and prevent further progression of the existing infection (that is, therapeutic GT) in addition to standard antibacterial and antifungal therapy. A retrospective analysis was performed on 28 consecutive pediatric SCT recipients who received at least one dose of GT between March 2003 and November 2013 at a single institution. All donors were conditioned with G-CSF+dexamethasone with harvest performed 12-18 h later. Indications for SCT were acute leukemia in 46% (13/28) and severe aplastic anemia in 21% (6/28). The main indications for GT were invasive fungal disease in 50%, bacterial infection in 21% and co-morbidities with predicted reduced tolerance to sepsis in 18% (5/28). The median number of GT was 6 (range 1-14) with a median dose of 3.56 × 10 10 granulocytes infused. The median increment in ANC was 1.06 × 10 9 /L and correlated with the granulocyte dose infused. Adverse reactions observed were mild and infrequent. Sixty-four percent of patients (18/28) are alive with only 2 of the 10 deaths being related to progression of infection. In addition there was a low overall incidence of grade 3-4 acute mucositis and a very low incidence (7%) of acute GvHD grade 3-4. Single-donor GTs afford protection to children undergoing SCT at additional risk of infection and may reduce the overall incidence of severe GvHD.

show abstract

“…In fi ve of the seven studies, a certain degree of success following the GT treatment was documented. In 3, there was a signifi cant overall benefi t (16)(17)(18) and in two in certain groups of patients only (13,15). By contrast, two studies reported the overall negative results for GT (14,19).…”

Section: The Thrilling Story Of Granulocyte Transfusions: Enthusiastimentioning

confidence: 97%

“…In the 1970s, when granulocytes from healthy donors were already employed, the results of the studies became more contradictive, showing positive results, but partial or no benefi cial effect as well. Seven studies of therapeutic GT reported on the response of infected neutropenic patients to treatment with GT plus antibiotics versus patients given antibiotics alone (13)(14)(15)(16)(17)(18)(19). In fi ve of the seven studies, a certain degree of success following the GT treatment was documented.…”

Section: The Thrilling Story Of Granulocyte Transfusions: Enthusiastimentioning

confidence: 99%

Granulocyte transfusions

Rimajova¹,

Sopko²,

Martinka³

et al. 2012

BLL

View full text Add to dashboard Cite

Neutrophils play an essencial role in the defense of the body against bacterial and fungal infections. Disorders of their number or function signifi cantly increase the risk of life-threatening infection. In spite of the development of growth factors, new broad spectrum antibiotics and antifungal drugs against nearly all known pathogens, severe neutropenia associated with bacterial or invasive fungal infections remains a major cause of morbidity and mortality in patients undergoing aggressive cancer chemotherapy or hematopoietic stem cell transplantation. Lately, an interest about granulocyte transfusions was renewed, what is a logical approach in the management of patients with prolonged 'reversible' severe neutropenia and severe infection, which is not controlled with appropriate antimicrobial and supportive treatment, including recombinant hematopoietic growth factors. It was a consequence of advances in the fi eld of apheresis science, use of sedimenting agents and expecially advances in mobilization of granulocytes to the peripheral blood. It became now possible to collect large numbers of neutrophils. Therefore, the clinical use of granulocyte trasfusions, as a potential life saving treatment option in patients with severe neutropenia and uncontrolled infection in spite of appropriate antimicrobial therapy should be considered, with regard to possible benefi ts and risks (Ref. 74). Full Text in PDF www.elis.sk.

show abstract

A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia

Cited by 166 publications

References 22 publications

Granulocyte transfusions in the G-CSF era. Where do we stand?

Granulocyte transfusions in the G-CSF era. Where do we stand?

Single-donor granulocyte transfusions for improving the outcome of high-risk pediatric patients with known bacterial and fungal infections undergoing stem cell transplantation: a 10-year single-center experience

Granulocyte transfusions

Contact Info

Product

Resources

About